Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Didox (NSC-324360) 是一种合成的核糖核苷酸还原酶抑制剂,可降低患有痴呆症的 HIV 患者大脑中氧化损伤标志物的水平。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 130 | 现货 | ||
5 mg | ¥ 276 | 现货 | ||
10 mg | ¥ 397 | 现货 | ||
25 mg | ¥ 834 | 现货 | ||
50 mg | ¥ 1,290 | 现货 | ||
100 mg | ¥ 1,990 | 现货 | ||
500 mg | ¥ 4,370 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 295 | 现货 |
产品描述 | Didox (NSC-324360) is a synthetic ribonucleotide reductase (RR) inhibitor that has been found to reduce the levels of oxidative injury markers in the brains of HIV patients with dementia. |
体外活性 | Didox引起细胞死亡,而这一效应通过补充铁质得到抑制。Didox处理导致细胞铁含量、TfR1和铁蛋白水平发生变化,这与铁螯合剂deferoxamine(DFO)和deferiprone(DFP)造成的效果相当。Didox是一种双齿铁螯合剂,具有两个理论上可能的结合位点,其中以catechol基团的两个羟基作为配体的是更可能的一种。Didox的铁螯合特性可能通过阻断Tyr122上酪氨酸自由基的形成(如HU)以及通过捕获RRM2(对其活性至关重要)和细胞增殖所需的铁,从而对其抗肿瘤活性贡献。 |
体内活性 | Didox处理小鼠源骨髓诱发的肥大细胞(BMMC)时,降低了IgE刺激下的脱颗粒反应和包括IL-6、IL-13、TNF及MIP-1a (CCL3)在内的细胞因子产生[2]。 |
细胞实验 | The cells were seeded in a 96-well plate (at a density of 2 × 10^3 cells for HA22T/VGH;?1.5 × 103 cells for HuH7) and exposed to various concentrations of didox and only HA22T/VGH also to hydroxyurea, DFO or DFP (0, 1, 10, 25, 50, 100, 200 and 500 μM) for 24, 48 and 72 h. In other experiments, HA22T/VGH were seeded in 96-well plates and treated with a single dose of didox, HU, DFO, DFP alone or in combination with increasing doses of FAC (25, 50, 100, 200 and 400 μM) for 48–72 h. In other type of treatment,?HA22T/VGH cells were or pre-treated for 16 h with a single dose of didox (200 μM) and then treated in combination with FAC (400–800 μM) or directly in combination didox-FAC for 48–72 h.Cell viability was evaluated with an MTT assay.?After the indicated time points and treatments, the supernatant was removed and 100 μL of the MTT solution (0.5 mg/mL) diluted in the cell medium was added to the wells.?After 3.5 h of incubation at 37 °C and 5% CO2, the MTT medium was removed and 75 μL of DMSO was added to each well.?Plates were shaken for 15 min at 37 °C until complete dissolution and absorbance was measured at 540 nm emission wavelengths.?Average percentage of cell viability at each concentration was calculated using Microsoft Excel 2016 software[1]. |
别名 | 3,4-二羟基苯甲羟肟酸, NSC-324360 |
分子量 | 169.13 |
分子式 | C7H7NO4 |
CAS No. | 69839-83-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (591.26 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 5.9126 mL | 29.5631 mL | 59.1261 mL | 147.8153 mL |
5 mM | 1.1825 mL | 5.9126 mL | 11.8252 mL | 29.5631 mL | |
10 mM | 0.5913 mL | 2.9563 mL | 5.9126 mL | 14.7815 mL | |
20 mM | 0.2956 mL | 1.4782 mL | 2.9563 mL | 7.3908 mL | |
50 mM | 0.1183 mL | 0.5913 mL | 1.1825 mL | 2.9563 mL | |
100 mM | 0.0591 mL | 0.2956 mL | 0.5913 mL | 1.4782 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Didox 69839-83-4 Cell Cycle/Checkpoint DNA Damage/DNA Repair DNA/RNA Synthesis NSC 324360 Inhibitor 3,4-二羟基苯甲羟肟酸 inhibit NSC-324360 NSC324360 inhibitor